FDA Asks Panel To Consider If Salix's Xifaxan Caused Patient Deaths In Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Salix's Xifaxan for hepatic encephalopathy faces questions over possible excess deaths and the subjectivity of the primary endpoint in the single pivotal trial.